Pharmalot… Pharmalittle… Good Morning
Make a commentBy Ed Silverman // January 18th, 2012 // 7:53 am
Hello, everyone, and how are you today? Sunny skies are emerging here on the Pharmalot corporate campus, where we are brewing a delicious cup of stimulation - Rain Forest Nut, in this case - and hustling to tend to various matters as another busy day lies ahead. We trust you can relate. So let us not dilly or dally. A few tidbits can be found below. We hope you have a productive day and conquer the world. Meanwhile, do stay in touch…
J&J Has Enough Doxil For Patients On Waiting List (Dow Jones)
J&J Memo Told Reps To Push Risperdal For Kids (Bloomberg News)
EMA OKs Genzyme Fabrazyme Plant In Massachusetts (Dow Jones)
J&J Opens Biotech Startup Center (Xconomy)
Columbia Labs Gel To Reduce Pre-Terms Births Is Not Effective (Bloomberg News)
FDA Approves BTG Drug For Cancer Toxicity (Reuters)
Bayer Colorectal Cancer Drug Improves Survival: Study (Dow Jones)
EDITOR’S NOTE: Please check this post for updates throughout the morning
sunrise pic thx to benimoto on flickr
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
Bayer, Ben Venue Laboratories, Biotech, Boehringer Ingelheim, BTG, Cancer, Colorectal Cancer, Columbia Laboratories, Doxil, Drug Shortages, EMA, European Medicines Agency, Fabrazyme, Genzyme, JJ, Johnson & Johnson, Off Label Marketing, Pre-Term Birth, Pregosterone Gel, Prescription Drug Shortages, Risperdal, San Diego, Sanofi, Texas